Belgium seizes fake weight-loss drugs containing insulin
Send a link to a friend
[October 31, 2023]
By Patrick Wingrove
(Reuters) - Belgium’s drug regulator said it had seized counterfeit
versions of semaglutide, the active ingredient in Novo Nordisk's popular
obesity drug Wegovy, in which the injector pens contained insulin.
The Federal Agency for Medicines and Health Products told Reuters that
this year it had detained nine mailed packages of GLP-1 medicines, the
class of drugs that includes Wegovy and Novo's diabetes drug Ozempic, on
the suspicion that they were fake.
It said two of those packages were found to contain drugs that had not
been manufactured by Novo Nordisk or another GLP-1 drugmaker.
A lab analysis confirmed that one contained insulin, according to the
agency, which is used to treat diabetes and can cause serious health
issues such as hypoglycemia - dangerously low blood sugar - and seizures
when not administered properly.
Several people were hospitalized in Austria after using suspected fake
versions of Ozempic, health regulators there reported last week.
![](http://archives.lincolndailynews.com/2023/Oct/31/images/ads/current/elkhart_fertilizer_sda_FFARM_2023.png)
The country’s health safety regulator, BASG, said the patients had
suffered side effects that indicated the product contained insulin
instead of semaglutide, but did not say whether that had been confirmed
through testing.
Britain on Thursday warned the public about buying potentially fake
weight-loss pens claiming to be Ozempic or Novo Nordisk's older
weight-loss drug Saxenda after reports of a "very small number" of
hospitalizations.
[to top of second column]
|
![](../images/103123PIX/health24.jpg)
A selection of injector pens for the Wegovy weight loss drug are
shown in this photo illustration in Chicago, Illinois, U.S., March
31, 2023. REUTERS/Jim Vondruska/Illustration/File Photo
![](http://archives.lincolndailynews.com/2023/Oct/31/images/ads/current/peasleymemorials_lda_2022.png) Surging demand for Ozempic and other
drugs that can be used for weight-loss has led to a shortage of
those medicines and a spate of counterfeits.
A spokesperson for Australia's health regulator, the Therapeutic
Goods Administration, said the agency had identified 14 cases of
counterfeit obesity drugs this year.
Belgium’s health minister said last week the country wanted to
temporarily ban the use of Ozempic as a weight loss treatment for a
few weeks or months to deal with a shortage of the medicine, which
is approved to treat type 2 diabetes, the original use for GLP-1
drugs.
Law enforcement, anti-counterfeiting and public health officials
have said they are opening inquiries into complaints of fake drugs,
trolling e-commerce and social media for purchase offers or
advertisements, and training customs officials on how to spot
counterfeits to help stem the surge.
(Reporting by Patrick Wingrove in New York; Editing by Bill Berkrot)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |